Sign up USA
Proactive Investors - Run By Investors For Investors

PreveCeutical Medical inks research agreement with University of Queensland to develop non-addictive painkillers

PreveCeutical said the parties intend to conduct a research programme which expands the use of their disulfide linker technology and seeks to develop non-addictive analgesics for the treatment of pain, which may offer an alternative to addictive opioids
Drug research
PreveCeutical said, under the agreement, it will own all intellectual property developed under the research programme

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has entered into a research and option agreement with the University of Queensland (UQ) and UniQuest Pty Limited, the university’s main commercialisation company to develop non-addictive painkillers.

Under the agreement, PreveCeutical said the parties intend to conduct a research programme which expands the use of their disulfide linker technology and seeks to develop non-addictive analgesics for the treatment of pain, which may offer an alternative to addictive opioids. 

The health sciences company – which develops innovative preventive therapies utilising organic and nature identical products - noted that the US opioid epidemic has led to significant numbers of opioid-related deaths and addictions, taxing public health care systems and affecting social and economic welfare.

The group said the multiphase research program will involve peptide library synthesis pharmacological evaluation, and acute pharmacokinetic assessment and efficacy determinations in appropriate models of pain and inflammation.

The programme has a targeted start date of  1 March 2018, and will be led by UQ researcher and PreveCeutical’s chief research officer, Dr. Harendra Parekh, in collaboration with the UQ School of Pharmacy’s pain and inflammation pharmacology expert, associate professor Peter Cabot.

PreveCeutical said, under the agreement, it will own all intellectual property developed under the research program and will be granted an option to negotiate an exclusive, worldwide licence to UniQuest’s background intellectual property. 

As consideration for the licence, the company will pay UniQuest sales-based royalties and certain amounts upon the achievement of predetermined development milestones. 

View full PREV profile View Profile

PreveCeutical Medical Inc Timeline

Related Articles

1506367758_shutterstock_118491940.jpg
September 26 2017
The firm received an order for its clinical research use only (RUO) kits from a large, multinational pharma company
cancer cell
January 31 2018
The highlights included successful US and European ovarian cancer studies that underlined the potential of the company’s Parsortix liquid biopsy system
leg bones
March 31 2018
"We are now in the position of really trying to kick on in 2018"

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use